Successful transaction: Adragos Pharma has officially taken over the Sanofi production site in Kawagoe, Japan
- Adragos Pharma now third largest pure-play CDMO in the Japanese market
- Long-term agreement with Sanofi secures local healthcare supply
Munich / Paris / Tokyo, March 02, 2023 – Munich-based pharmaceutical contract manufacturer (CDMO) Adragos Pharma GmbH successfully completed the acquisition of one of Japan's leading pharmaceutical manufacturing facilities from Sanofi K.K. The transaction makes Adragos Pharma the third largest pure-play contract manufacturer in Japan, one of its three core markets. The acquisition also kicks off a long-term supply agreement between the CDMO and Sanofi. Kawagoe Pharma will continue to produce for Sanofi and the Japanese market as a strategic partner, thus playing an essential role for the local healthcare system.
The official handover of the production facility took place yesterday in the presence of the workforce, which will remain at the site, as well as of representatives of both companies.
The Kawagoe site near Tokyo is one of the largest and most technically advanced of its kind in Japan. Under Sanofi, oral solids and ampoules were manufactured here. In addition, the site provided packaging, visual inspection, and QC test services for the Japanese and Asian markets.
Jeremy Goldnadel, International Cluster Head, Manufacturing and Supply, of Sanofi expressed, "I would like, in the name of Sanofi, to express our deepest gratitude to the highly professional employees at the Kawagoe site over our long 50-years history, and looking forward, wish them all the success and bright future at Adragos Pharma. We are convinced that our long-term partnership will ensure the supply of high quality medicines generating the greatest possible benefit for patients in Japan."
Dr. Andreas Raabe, CEO of Adragos Pharma: "With this acquisition, we have taken an important step towards becoming a leading global CDMO. Our goal is to introduce new customers from Europe, North America and the Japanese domestic market to the production site, as well as to further expand the site's services and capabilities for Sanofi and future customers."
Marco Gorgas, CTO at Adragos Pharma, explains, "The site's capabilities and resources provide a solid foundation for future growth. Both Sanofi and our new customers can rely on our full commitment to providing affordable, high-quality products to patients."
The exact terms of the transaction are not disclosed.
About Adragos
Adragos Pharma is a globally operating CDMO with headquarters in Munich, Germany. Its declared goal is to expand its existing production network through acquisitions in Europe, North America, and Japan to attain a globally leading position within the next few years and set new standards in customer service and data centricity. In its buy-and-build growth strategy, Adragos Pharma is supported by FSN Capital, a leading Northern European private equity firm, and Prange Group, a diversified leading German family office. Adragos Pharma currently operates four production sites in France, Germany, and Japan (as of March 1, 2023).
Here you can find images to download for your story. We are grateful for a publication reference.
Contacts
press@adragos-pharma.com
Links
About news aktuell GmbH
As wholly owned subsidiary of dpa, news aktuell provides business and organizations with effective access to media and consumers. Via the smart tools ots and zimpel, PR content accesses all media formats, including classical print, high click-rate online portals and social networks. In addition, news aktuell publishes all its customers’ PR content on www.presseportal.de, one of the PR portals with the greatest reach in Germany. By this means, all the relevant multipliers are reached globally, from editors, via digital influencers right up to specialist bloggers and interested consumers. news aktuell has been on the market since 1989. The company, with a staff complement of more than 135, has its headquarters in Hamburg. Other offices are in Berlin, Dusseldorf, Frankfurt und Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site29.4.2025 14:00:00 CEST | Press Release
The company announced its successful approval by the U.S. Food and Drug Administration (FDA) for the manufacturing, testing and release of recombinant Cas9 nuclease from its headquarters site. Cas9 is an essential component of CRISPR-based gene editing therapies, including CASGEVY® (exagamglogene autotemcel) developed and launched by Vertex Pharmaceuticals. Biomay's recent achievement refers to an inspection by the FDA's Center for Biologics Evaluation and Research (CBER) at Biomay's headquarters manufacturing site in Vienna, Seestadt in December 2024. No observation was found, and no Form FDA 483 was issued by the authority, allowing Biomay's headquarters site to supply Cas9 for the United States. Biomay operates two independent cGMP manufacturing sites, a headquarters facility in Vienna Seestadt, and a second site in Vienna downtown. The authority’s approval of Biomay's headquarters site represents the company's second successful FDA inspection following the 2023 approval of Biomay's
Growth and innovation as cornerstones of a strong democracy and a digitally sovereign Europe29.4.2025 12:00:00 CEST | Pressmeddelande
Germany should be restored to a growth path and should give new impulse to innovation, along with its European partners. Because prosperity is a significant guarantor of a stable democracy. Digital sovereignty is the anchor of a strong Europe. Germany can once again be a country of pioneering innovation and a pacesetter for the continent. For this, comprehensive modernization of the state is indispensable. The Bertelsmann Stiftung presented its proposals at the annual press conference.
Acousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR Study29.4.2025 09:00:00 CEST | Press Release
Tübingen, Germany, April 29, 2025 Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN: bimokalner) for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy.
Australia’s next government must mend structural cracks appearing in its political, economic and social foundation, report finds25.4.2025 12:05:00 CEST | Pressmeddelande
- Picture is available at AP - Los Angeles/DNA - Australia boasts some of the world’s most sophisticated political institutions and one of its wealthiest economies. But this veneer of success masks deeper structural issues — and a “ticking time bomb” of overreliance on extractive industries must be addressed under Australia’s next government, a new report recommends.
DYMO® LETRATAG 200B VINNER DET PRESTIGEFYLLDA PRISET ”BUSINESS PRODUCT OF THE YEAR” - STRUKTURERAR OCH ORGANISERAR VARDAGEN24.4.2025 16:44:06 CEST | Press Release
Amsterdam – vikten av organisering, effektivitet och produktivitet i både personliga och professionella sammanhang har aldrig varit större. Detta då allt fler använder smarta lösningar för att förenkla sin vardag. DYMO®, en ledande leverantör av innovativa etikett- och utskriftslösningar, ligger här i framkant. Som ett erkännande har DYMO LetraTag 200B belönats med EOPA Best Business Product Award, en utmärkelse som lyfter fram hur den förenklat organisering både hemma och på kontoret. "Trenden mot smart självorganisering fortsätter", berättar Liesbet De Soomer, Global Marketing Director på DYMO. "LetraTag 200B stödjer utveckligen genom att erbjuda en användarvänlig lösning, som gör märkningen snabb och enkel. Med det här verktyget kan användaren strukturera vardagskaoset och organisera tillvaron.” EOPA Best Business Product Award, som delas ut årligen, uppmärksammar produkter som sticker ut för sitt nytänkande, sin funktionalitet och sin användarvänlighet. LetraTag 200B:s utmärkelse b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom